Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma

Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma - Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034312

Enrollment

Registered

2018-12-01

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant pleural mesothelioma

Interventions

Malignant pleural mesothelioma of unresectable progression and recurrence exacerbated after cancer chemotherapy Elderly subjects with non-tumor types (including mesothelioma), non-asbestos exposure an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Malignant pleural mesothelioma of unresectable progression and recurrence exacerbated after cancer chemotherapy

Exclusion criteria

Exclusion criteria: Initial and resectable malignant pleural mesothelioma

Design outcomes

Primary

Measure	Time frame
Comprehensive station immune dynamics using peripheral blood before Bivolbam administration, 5 to 7 days after administration and after about 3 months	—

Secondary

Measure	Time frame
Search biomarkers after analysis	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactYasumitsu Nishimura

Kawasaki Medical School Department of Hygiene

yas@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026